Advanced search

Authors whose works are in public domain in at least one jurisdiction

List of works by Hartmut Goldschmidt

1-50 of 422 results

View this query on the Wikidata Query Service
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

scientific article published in June 2005
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

scientific article
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

scientific article published on 3 August 2015
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

scientific article
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

scientific article
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

scientific article published on August 2016
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

scientific article
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

scientific article published on 09 August 2007
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

scientific article published on 03 February 2011
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

scientific article published on 21 March 2016
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

scientific article
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

scientific article published on 23 June 2010
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

scientific article published on 08 December 2011
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

scientific article
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature

scientific article
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

scientific article
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

scientific article published on 18 August 2008
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials

scientific article
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

scientific article
CD200 is a new prognostic factor in multiple myeloma

scientific article published on 31 August 2006
Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma

scientific article published on 22 February 2010
Targeting the BRAF V600E mutation in multiple myeloma

scientific article
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk

scientific journal article
Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement

scientific article published on 20 January 2015
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

scientific article
Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load

scientific article published on 21 October 2013
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

scientific article
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

scientific article published on 23 August 2017
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma

scientific article
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation

scientific article
Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk

scientific journal article
Malignancy in renal transplantation

scientific article published on June 2004
A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

scientific article
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.

scientific article published on 12 March 2013
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up

scientific article published on 05 July 2011
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

scientific article
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor

scientific article published on 18 February 2009
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

scientific article published on 01 May 2019
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

scientific article published in January 2008
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma

scientific article
Induction of angiogenesis by normal and malignant plasma cells.

scientific article published on 18 March 2009
Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death.

scientific article published on 9 October 2007
A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study

scientific article published in January 2009
Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation

scientific article published on 17 November 2009
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

scientific article published on 01 March 2012
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

scientific article
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

scientific article published on 08 June 2018
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

scientific article
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma

scientific article
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance

scientific article published on 11 December 2012

Paulina is supported by:

About Paulina

Help